11,714 Results

FDA accepts NDA for Libervant Buccal Film for the treatment of seizure clusters. -Aquestive Therapeutics.

 Added 1 day ago

Aquestive Therapeutics, Inc. announced that, as anticipated, the FDA accepted the Company’s New Drug Application (NDA) for Libervant (diazepam) Buccal...

FDA approves Trulicity to reduce major adverse cardiovascular events in type 2 diabetes patients Eli Lilly

 Added 2 days ago

The FDA has approved Trulicity (dulaglutide) for the reduction of major adverse cardiovascular events (MACE) in adults with type 2...

FDA approves Nexletol to treat heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease - Esperion.

 Added 2 days ago

Esperion has announced that the FDA approved Nexletol (bempedoic acid) tablet, an oral, once-daily, non-statin LDL-Cholesterol (LDL-C) lowering medicine. Nexletol...

FDA approves Anjeso to treat moderate to severe pain.- Baudax Bio

 Added 2 days ago

Baudax Bio, Inc. announced that the FDA has approved the New Drug Application (NDA) for Anjeso (meloxicam injection), which is...

Interim data from the SIERRA trial of Iomab-B shows side effect differences in Acute Myeloid Leukemia patients.- Actinium Pharma

 Added 2 days ago

Actinium Pharmaceuticals announced findings from the SIERRA trial of Iomab-B (monoclonal antibody BC8 / I-131) in Elderly Relapse/Refractory Acute Myeloid...

FDA approves Vyepti for migraine prevention.- Lundbeck

 Added 2 days ago

Lundbeck has announced that Vyepti (eptinezumab-jjmr) has been approved by the FDA for the preventive treatment of migraine in adults...

Teva Pharmaceutical Industries Ltd. announced deutetrabenazine failed to meet the endpoint in in Phase II/III trials to treat tics in pediatric patients with Tourette Syndrome.

 Added 3 days ago

Teva Pharmaceutical Industries Ltd. announced the Phase II/III ARTISTS 1 and Phase III ARTISTS 2 trials designed to evaluate deutetrabenazine...

Tocagen and Forte Biosciences to merge.

 Added 3 days ago

Tocagen Inc. and Forte Biosciences, Inc., a privately held clinical-stage biopharmaceutical company developing a live biotherapeutic for the treatment of...

Phase III ESCAPE-NA1 study of nerinetide suggests potential to treat stroke.- NoNo Inc

 Added 3 days ago

NoNO Inc reported results from the pivotal Phase III ESCAPE-NA1 study, a multicenter, randomized, double-blinded, placebo-controlled, parallel group, single-dose study...

Intra-Cellular Therapies, Inc. announced the publication in JAMA Psychiatry of Caplyta trial (ITI-007-301) in adult patients with schizophrenia.

 Added 3 days ago

Intra-Cellular Therapies, Inc. announced the publication of results from its Caplyta (lumateperone) clinical trial (ITI-007-301) in adult patients with schizophrenia....

Load more